EGA | European Generic medicines Association

EUROPEAN GENERIC MEDICINES ASSOCIATION

Making Medicines Affordable

Home

Generic Medicines

Biosimilar Mediciness

Documents & Positions

What’s New? | Myths & Realities | Fact Sheets |

Breaking News

EGA PRESS RELEASE | 8 July 2009

EUROPEAN COMMISSION INQUIRY RECOMMENDS SYSTEMIC
IMPROVEMENTS TO ENSURE IMMEDIATE ACCESS FOR PATIENTS
TO AFFORDABLE GENERIC MEDICINES UPON PATENT EXPIRY

The EGA welcomes the European Commission’s Final Report on the Pharmaceutical Sector Inquiry and calls on European and national authorities for quick implementation of the conclusions and recommendations. More...

EGA Commission Documents | Final Report (8 July 2009)

Commission Communication | de en fr
Commission Staff Working Document
(Technical annex to the Commission Communication)
| Part 1 | Part 2
Citizens' Summary
Press release | Antitrust: shortcomings in the pharmaceutical
sector require further action | IP/09/1098
FAQ | Frequently asked questions on the final report of the
sector inquiry into pharmaceuticals | MEMO/09/321
Fact Sheet 1 | Fact Sheet 2 | Fact Sheet 3

NEW! Revised & Updated Edition with Additional Country Data

HOW TO INCREASE PATIENT ACCESS TO GENERIC MEDICINES IN EUROPEAN HEALTHCARE SYSTEMS

A Report by the
EGA Health Economics Committee

“EU governments need to ensure fast generic medicines uptake, as market access and low market volume in key EU countries is still a real problem and is having a major negative impact on patient access to more affordable treatments.” More...

Press Release
The Report | Revised & Updated

Latest News

PRESS RELEASE | 21 January 2010EGA CALLS FOR IMPROVED REGULATORY FRAMEWORK WITH VISION 2015 TO CREATE A STRONGER EUROPEAN GENERIC MEDECINE INDUSTRY AND INCREASED PATIENT ACCESS TO AFFORDABLE HEALTHCARE.

Greg Perry, director general of the European Generic medicines Association (EGA) opened the 9th edition of the EGA Scientific and Regulatory Affairs Conference in London, by reiterating the association’s vision to create an improved European regulatory framework for generic and biosimilar medicines. More...

PRESS RELEASE | 20 January 2010KEEP IN MIND THE OBJECTIVES OF THE EC PHARMACOVIGILANCE LEGISLATIVE PROPOSALS: IMPROVING THE EU PHARMACOVIGILANCE SYSTEM AND CUTTING RED TAPE.

During the ongoing codecision procedure, policy makers must keep in mind the objectives of the European Commission pharmacovigilance legislative proposals which consist in strengthening, but also streamlining and rationalising, the Community pharmacovigilance system with a view to preventing unnecessary patient exposure to risks. This was the key message given by Suzette Kox, EGA Senior Director Scientific Affairs, at the EGA’s 3rd Pharmacovigilance Discussion Forum in London today. A number of national competent authorities and the European Consumers’ Organisation participated in the forum. More...

PRESS RELEASE | 18 November 2009 “STAKES ARE HIGHER THAN EVER FOR THE IMMEDIATE THREE YEARS AHEAD” SAYS DIDIER BARRET NEWLY ELECTED PRESIDENT OF THE EUROPEAN GENERIC MEDICINES ASSOCIATION (EGA)

The European Generic medicines Association (EGA) welcomes Didier Barret as its new President, unanimously elected by the EGA Board of Directors today in Brussels. More...

PRESS RELEASE | 10 November 2009 STOP FAKE MEDICINES: FOCUS ON SUPPLY CHAIN INTEGRITY AND CRIMINALISATION SAY MEPS AND EXPERTS

Policy makers must shift the focus away from technological measures to stop counterfeiting of medicines and look at real and effective solutions such as implementing and increasing criminal sanctions while ensuring that all parties do business only with certified and reliable partners. More...
Ms Antonyia Parvanova MEP introductory speech
Greg Perry's presentation

PRESS RELEASE | 2 October 2009 THE EU PHARMACEUTICAL SECTOR INQUIRY RECOMMENDATIONS - NOT TENDERING SYSTEMS - PROVIDE THE KEY TO INCREASING PATIENT ACCESS TO AFFORDABLE GENERIC MEDICINES

“Tendering is undermining the long-term patient access to generic medicines” and “it is urgent that governments start to see that pricing and reimbursement measures must be about more than just short term price decreases”, said Eric Gorka EGA President More..

EGA PUBLICATION | 2 September 2009 EGA Conference Highlights | 05

The key moments and messages from the 15th EGA Annual Conference in Barcelona and the 7th EGA the Symposium on Biosimilar Medicines.

EGA PUBLICATION | 4 June 2009 EGA Conference Highlights | 04

“Competitive, Cost-Effective Generic Medicines Struggle to Overcome Major Hurdles”
The key moments and messages from the conferences organised by the EGA during the first half of 2009.

Leading Issues

Pharmaceutical Package 2008 EC Sector Inquiry into Pharmaceuticals

Forthcoming Events

6th EGA Legal Affairs Forum
Munich | 11 March 2010

BIOSIMILAR MEDICINES:
8th EGA Annual International Symposium
London | 22-23 April 2010

3rd EGA-EMA-CMD(h) Symposium on Bioequivalence "Training for Industry on the Revised Bioequivalence Guideline with Pharmacokinetic Assessors"
London | 28 April 2010 (TBC)

Rome 16th EGA Annual Conference
Rome | 2-4 June 2010

Details avavible soon!